AARP New Hampshire volunteers showed up in full force at the NH State House on January 21 for Senate committee hearings regarding legislation that will help to #StopRxGreed for Granite State residents.
It is getting expensive out there! Retail prices for 267 brand-name drugs commonly used by older adults surged by an average of 5.8% in 2018, more than twice the general inflation rate of 2.4%, according to new AARP Public Policy Institute data.
It’s well known that prescription drug prices are skyrocketing in America. Price increases for brand-name drugs have far exceeded the rate of inflation since at least 2006, according to AARP’s Rx Price Watch report.
AARP New Hampshire today released new state data and an infographic illustrating the impact of high prescription drug prices for Granite State residents, specifically those living with cancer, prediabetes or diabetes, and heart disease. AARP unveiled the infographic at the National Academy for State Health Policy (NASHP) annual conference as part of AARP’s nationwide Stop Rx Greed campaign to lower drug prices for all Americans.
AARP Executive Vice President and Chief Advocacy and Engagement Officer Nancy LeaMond issued the following statement after the administration announced a Notice of Proposed Rulemaking (NPRM) concerning the importation of prescription drugs:
AARP New Hampshire Applauds the Strong Bipartisan Senate Finance Committee Vote for the Prescription Drug Pricing Reduction Act of 2019
AARP New Hampshire State Director Todd Fahey issued the following statement, applauding Senator Maggie Hassan for voting in favor of the Senate Finance Committee’s Prescription Drug Pricing Reduction Act of 2019:
Search AARP New Hampshire
Sign Up & Stay Connected